These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 27793693

  • 1. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
    Chen F, Huang X, Wu M, Gou S, Hu W.
    Cancer Lett; 2017 Jan 28; 385():168-178. PubMed ID: 27793693
    [Abstract] [Full Text] [Related]

  • 2. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F, Qin X, Xu G, Gou S, Jin X.
    Biochem Pharmacol; 2017 Jul 01; 135():50-68. PubMed ID: 28288821
    [Abstract] [Full Text] [Related]

  • 3. Emerging JWA-targeted Pt(IV) prodrugs conjugated with CX-4945 to overcome chemo-immune-resistance.
    Chen F, Pei S, Wang X, Zhu Q, Gou S.
    Biochem Biophys Res Commun; 2020 Jan 15; 521(3):753-761. PubMed ID: 31703842
    [Abstract] [Full Text] [Related]

  • 4. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.
    Siddiqui-Jain A, Bliesath J, Macalino D, Omori M, Huser N, Streiner N, Ho CB, Anderes K, Proffitt C, O'Brien SE, Lim JK, Von Hoff DD, Ryckman DM, Rice WG, Drygin D.
    Mol Cancer Ther; 2012 Apr 15; 11(4):994-1005. PubMed ID: 22267551
    [Abstract] [Full Text] [Related]

  • 5. CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response.
    Becherel OJ, Jakob B, Cherry AL, Gueven N, Fusser M, Kijas AW, Peng C, Katyal S, McKinnon PJ, Chen J, Epe B, Smerdon SJ, Taucher-Scholz G, Lavin MF.
    Nucleic Acids Res; 2010 Mar 15; 38(5):1489-503. PubMed ID: 20008512
    [Abstract] [Full Text] [Related]

  • 6. Hybrid of DNA-targeting Chlorambucil with Pt(IV) Species to Reverse Drug Resistance.
    Chen F, Xu G, Qin X, Jin X, Gou S.
    J Pharmacol Exp Ther; 2017 Nov 15; 363(2):221-239. PubMed ID: 28916659
    [Abstract] [Full Text] [Related]

  • 7. Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments.
    Wang Y, Wang X, Xu G, Gou S.
    J Med Chem; 2021 Apr 08; 64(7):4163-4178. PubMed ID: 33784109
    [Abstract] [Full Text] [Related]

  • 8. Disruption of SSBs repair to combat platinum resistance via the JWA-targeted Pt(IV) prodrug conjugated with a wogonin derivative.
    Wang X, Li L, Pei S, Zhu Q, Chen F.
    Pharmazie; 2020 Mar 20; 75(2):94-101. PubMed ID: 32213241
    [Abstract] [Full Text] [Related]

  • 9. Discovery of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine Derivatives as Highly Selective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition.
    Wang Y, Lv Z, Chen F, Wang X, Gou S.
    J Med Chem; 2021 Apr 22; 64(8):5082-5098. PubMed ID: 33834781
    [Abstract] [Full Text] [Related]

  • 10. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, Bliesath J, Omori M, Huser N, Ho C, Proffitt C, Schwaebe MK, Ryckman DM, Rice WG, Anderes K.
    Cancer Res; 2010 Dec 15; 70(24):10288-98. PubMed ID: 21159648
    [Abstract] [Full Text] [Related]

  • 11. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L, Huang X, Huang R, Gou S, Wang Z, Wang H.
    Eur J Med Chem; 2018 Aug 05; 156():666-679. PubMed ID: 30031977
    [Abstract] [Full Text] [Related]

  • 12. Molecular Pathways: Emergence of Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage Response and Repair Pathways in Cancer Cells.
    Rabalski AJ, Gyenis L, Litchfield DW.
    Clin Cancer Res; 2016 Jun 15; 22(12):2840-7. PubMed ID: 27306791
    [Abstract] [Full Text] [Related]

  • 13. Beclin1 affected by DN604 upregulates chemo-sensitivity of cervix SiHa cancer cells via inhibiting CK2-MRN-DSBs repair.
    Chen F, Sun S, Liu N, Pei S, Zhu Q, Wang X, Gou S.
    Anticancer Drugs; 2019 Sep 15; 30(8):774-783. PubMed ID: 31274516
    [Abstract] [Full Text] [Related]

  • 14. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A, Roolf C, Hamed M, Gladbach YS, Sender S, Konkolefski C, Knübel G, Sekora A, Fuellen G, Vollmar B, Murua Escobar H, Junghanss C.
    BMC Cancer; 2019 Mar 06; 19(1):202. PubMed ID: 30841886
    [Abstract] [Full Text] [Related]

  • 15. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
    Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E, Vialettes A, Whitten JP, Chen TK, Darjania L, Stansfield R, Bliesath J, Drygin D, Ho C, Omori M, Proffitt C, Streiner N, Rice WG, Ryckman DM, Anderes K.
    Mol Cell Biochem; 2011 Oct 06; 356(1-2):37-43. PubMed ID: 21755459
    [Abstract] [Full Text] [Related]

  • 16. Combination of 7-hydroxycoumarin in a platinum(IV) complex derived from cisplatin enhanced cytotoxicity with multiple mechanisms of action.
    Hua W, Zhao J, Hu W, Gou S.
    J Inorg Biochem; 2018 Sep 06; 186():17-23. PubMed ID: 29807243
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L, Fregona D.
    Chem Biol Interact; 2004 Jun 30; 148(1-2):37-48. PubMed ID: 15223355
    [Abstract] [Full Text] [Related]

  • 18. Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond.
    Kim J, Kim SH.
    Arch Pharm Res; 2012 Aug 30; 35(8):1293-6. PubMed ID: 22941473
    [Abstract] [Full Text] [Related]

  • 19. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
    Montagner D, Tolan D, Andriollo E, Gandin V, Marzano C.
    Int J Mol Sci; 2018 Nov 27; 19(12):. PubMed ID: 30486477
    [Abstract] [Full Text] [Related]

  • 20. Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer.
    Jung M, Park KH, Kim HM, Kim TS, Zhang X, Park SM, Beom SH, Kim HS, Cheong JH, Chung HC, Soong J, Lin SC, Rha SY.
    Gastric Cancer; 2019 Nov 27; 22(6):1153-1163. PubMed ID: 31098863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.